Login Register Cart 0
Generic placeholder image

Current Gene Therapy

Editor-in-Chief

ISSN (Print): 1566-5232
ISSN (Online): 1875-5631

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer

Author(s): Ke Wang, Yuanyuan Yu, Jian Zhao, Qianhao Meng, Chang Xu, Jing Ren, Yanqiao Zhang, Yusheng Wang* and Guangyu Wang*

Volume 24, Issue 2, 2024

Published on: 25 September, 2023

Page: [147 - 158] Pages: 12

DOI: 10.2174/0115665232247694230921060213

Price: $65

Abstract

Background: We aim to retrospectively explore the guiding value of the Lauren classification for patients who have undergone D2 gastrectomy to choose oxaliplatin plus capecitabine (XELOX) or oxaliplatin plus S-1 (SOX) as a further systemic treatment after the operation.

Methods: We collected data of 406 patients with stage III gastric cancer(GC)after radical D2 resection and regularly received XELOX or SOX adjuvant treatment after surgery and followed them for at least five years. According to the Lauren classification, we separated patients out into intestinal type (IT) GC together with non-intestinal type(NIT) GC. According to the chemotherapy regimen, we separated patients into the SOX group together with the XELOX group.

Results: Among non-intestinal type patients, the 3-year DFS rates in the SOX group and the XELOX group were 72.5%, respectively; 54.5% (P=0.037); The 5-year OS rates were 66.8% and 51.8% respectively (P=0.038), both of which were statistically significant.

Conclusion: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.

« Previous Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391(10125): 1023-75.
[http://dx.doi.org/10.1016/S0140-6736(17)33326-3] [PMID: 29395269]
[3]
Li C, Oh SJ, Kim S, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology 2009; 77(3-4): 197-204.
[http://dx.doi.org/10.1159/000236018] [PMID: 19729977]
[4]
Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet 2020; 396(10251): 635-48.
[http://dx.doi.org/10.1016/S0140-6736(20)31288-5] [PMID: 32861308]
[5]
Lauren P. The two histological main types of gastric carcinoma:Diffuse and so called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
[http://dx.doi.org/10.1159/000236018] [PMID: 19729977]
[6]
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76(2): 182-8.
[7]
Chen YC, Fang WL, Wang RF, et al. Clinicopathological variation of lauren classification in gastric cancer. Pathol Oncol Res 2016; 22(1): 197-202.
[http://dx.doi.org/10.1007/s12253-015-9996-6] [PMID: 26502923]
[8]
Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013; 31(7): 868-75.
[http://dx.doi.org/10.1200/JCO.2012.44.4612] [PMID: 23341533]
[9]
Graziano F, Arduini F, Ruzzo A, et al. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 2004; 10(8): 2784-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-03-0320] [PMID: 15102685]
[10]
Hommel C, Knoedler M, Bojarski C, et al. Diffuse gastric cancer with peritoneal carcinomatosis can mimic Crohn’s disease. Case Rep Gastroenterol 2012; 6(3): 695-703.
[http://dx.doi.org/10.1159/000345385] [PMID: 23185152]
[11]
Qiu MZ, Cai MY, Zhang DS, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med 2013; 11: 58.
[http://dx.doi.org/10.1054/bjoc.2000.1602]
[12]
Zheng H, Takahashi H, Murai Y, et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: An immunostaining study on the tissue microarray. J Clin Pathol 2006; 60(3): 273-7.
[http://dx.doi.org/10.1136/jcp.2006.038778] [PMID: 16714395]
[13]
Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975- 1989. Br J Cancer 2001; 84(3): 400-5.
[http://dx.doi.org/10.1054/bjoc.2000.1602]
[14]
Palestro G, Pellicano R, Fronda GR, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol 2005; 11(45): 7131-5.
[http://dx.doi.org/10.3748/wjg.v11.i45.7131] [PMID: 16437659]
[15]
Pereyra L, Gómez EJ, Mella JM, et al. Adenocarcinoma gástrico difuso asociado a enfermedad de Ménétrier. Acta Gastroenterol Latinoam 2011; 41(2): 142-5.
[PMID: 21894728]
[16]
Stiekema J, Cats A, Kuijpers A, et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol 2013; 39(7): 686-93.
[http://dx.doi.org/10.1016/j.ejso.2013.02.026] [PMID: 23498364]
[17]
Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M, Shinomura Y. Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion 2011; 83(4): 241-9.
[http://dx.doi.org/10.1159/000320453] [PMID: 21273772]
[18]
Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol 2014; 20(19): 5679-84.
[http://dx.doi.org/10.3748/wjg.v20.i19.5679]
[19]
Del Arco DC, Muñoz EL, Medina OL, et al. Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer. World J Gastrointest Oncol 2022; 14(6): 1162-74.
[http://dx.doi.org/10.4251/wjgo.v14.i6.1162]
[20]
Wang H, Xing XM, Ma LN, et al. Metastatic lymph node ratio and Lauren classification are independent prognostic markers for survival rates of patients with gastric cancer. Oncol Lett 2018; 15(6): 8853-62.
[http://dx.doi.org/10.3892/ol.2018.8497] [PMID: 29844813]
[21]
Liu L, Wang ZW, Ji J, et al. A cohort study and meta-analysis between histopathological classification and prognosis of gastric carcinoma. Anticancer Agents Med Chem 2013; 13(2): 227-34.
[http://dx.doi.org/10.2174/1871520611313020007] [PMID: 22934699]
[22]
Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg 2018; 267(1): 105-13.
[http://dx.doi.org/10.1097/SLA.0000000000002040] [PMID: 27759618]
[23]
Petrelli F, Berenato R, Turati L, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: A systematic review and meta-analysis. J Gastrointest Oncol 2017; 8(1): 148-63.
[http://dx.doi.org/10.21037/jgo.2017.01.10]
[24]
Wang K, Li E, Busuttil RA, et al. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020; 12: 1758835920930359.
[http://dx.doi.org/10.1177/1758835920930359]
[25]
Jiménez FP, Carmona-Bayonas A, Hernández R, et al. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON national cancer registry. Br J Cancer 2017; 117(6): 775-82.
[http://dx.doi.org/10.1038/bjc.2017.245] [PMID: 28765618]
[26]
Zheng Z, Jin X, He Q, et al. The efficacy of taxanes- and oxaliplatin-based chemotherapy in the treatment of gastric cancer after D2 gastrectomy for different lauren types. Medicine 2016; 95(6): e2785.
[http://dx.doi.org/10.1097/MD.0000000000002785] [PMID: 26871834]
[27]
Yu Y, Zhang Z, Meng Q, et al. Comparison of the efficacy of S- 1 plus oxaliplatin or capecitabine plus oxaliplatin for six and eight chemotherapy cycles as adjuvant chemotherapy in patients with stage II-III gastric cancer after D2 resection. Front Oncol 2021; 11: 684627.
[http://dx.doi.org/10.3389/fonc.2021.684627]
[28]
Cheng X, Yu S, Wang Y, et al. The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: A real-world study. Gastric Cancer 2019; 22(3): 587-97.
[http://dx.doi.org/10.1007/s10120-018-0895-x] [PMID: 30426294]
[29]
Huang SC, Ng KF, Yeh TS, et al. Subtraction of Epstein–Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases. Int J Cancer 2019; 145(12): 3218-30.
[http://dx.doi.org/10.1002/ijc.32215] [PMID: 30771224]
[30]
Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A. Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS One 2017; 12(9): e0183891.
[http://dx.doi.org/10.1371/journal.pone.0183891]
[31]
Schirren R, Novotny A, Oesterlin C, Slotta-Huspenina J, Friess H, Reim D. Significance of lauren classification in patients undergoing neoadjuvant/perioperative chemotherapy for locally advanced gastric or gastroesophageal junction cancers-analysis from a large single center cohort in germany. Cancers 2021; 13(2): 290.
[http://dx.doi.org/10.3390/cancers13020290]
[32]
van der Kaaij RT, Snaebjornsson P, Voncken FEM, et al. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma. Eur J Cancer 2017; 76: 27-35.
[http://dx.doi.org/10.1016/j.ejca.2017.01.031] [PMID: 28262585]
[33]
Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer 2017; 20(1): 175-81.
[http://dx.doi.org/10.1007/s10120-015-0581-1] [PMID: 26626800]
[34]
Wang G, Zhao J, Song Y, et al. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer. BMC Cancer 2018; 18(1): 547.
[http://dx.doi.org/10.1186/s12885-018-4480-9] [PMID: 29743043]
[35]
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): An open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 2021; 22(8): 1081-92.
[http://dx.doi.org/10.1016/S1470-2045(21)00297-7] [PMID: 34252374]
[36]
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012; 379(9813): 315-21.
[http://dx.doi.org/10.1016/S0140-6736(11)61873-4] [PMID: 22226517]
[37]
Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol 2012; 30(3): 268-73.
[http://dx.doi.org/10.1200/JCO.2011.39.1953]
[38]
Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S- 1 with oxaliplatin, and postoperative chemoradiation with S- 1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: The ARTIST 2 trial. Ann Oncol 2021; 32(3): 368-74.
[39]
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29(33): 4387-93.
[http://dx.doi.org/10.1200/JCO.2011.36.5908] [PMID: 22010012]
[40]
Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 2019; 37(15): 1296-304.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy